The Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab: The TezEx Study

Launched by GUY'S AND ST THOMAS' NHS FOUNDATION TRUST · Oct 29, 2024

Keywords

ClinConnect Summary

The TezEx Study is looking to understand why some patients with severe asthma continue to experience flare-ups, even while being treated with a medication called tezepelumab. This study is particularly focused on individuals who are eligible for tezepelumab, according to guidelines from the National Institute for Health and Care Excellence (NICE), and who either have not started the treatment yet or have recently begun it. The researchers want to gather information from participants about their experiences and symptoms during periods when their asthma worsens.

To be eligible for this study, participants need to be between 18 and 80 years old and must be willing to provide consent to join the study. They should also be able to attend check-ups when their asthma is not well controlled. However, individuals with certain other medical conditions or those who have issues with substance abuse may not be able to participate. The study is not yet recruiting, but it aims to help improve our understanding of asthma and enhance treatment options for those struggling with this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who qualify for tezepelumab according to NICE eligibility criteria and yet to begin treatment or those patients within 36 weeks (+/-8 weeks) since their first dose of tezepelumab at the Guy's severe asthma centre.
• • Age ≥ 18 and ≤ 80 years at tezepelumab initiation.
• • Able and willing to provide written informed consent and to comply with the study protocol, including being able to attend for assessment during a symptomatic deterioration.
• Exclusion Criteria:
• • Other clinically significant medical disease that is likely, in the opinion of the investigator, to require a change in biologic therapy or impact the ability to participate in the study.
• • History of current alcohol, drug, or chemical abuse or past abuse that would impair or risk the subject's full participation in the study, in the opinion of the investigator.
• • Other severe eosinophilic lung disease including EGPA, chronic eosinophilic pneumonia and ABPA
• • Severe bronchiectasis on CT causing daily sputum production
• • Maintenance therapy with an antibiotic including azithromycin or doxycycline
• • Inability to give written informed consent